Target General Information
Target ID T14597
Target Name Erbb2 tyrosine kinase receptor
Synonyms C-erbB-2; C-erbB-2 oncoprotein; Epidermal growth factor receptor 2; Erb2; HER-2; HER2 (erbB2/neu); HER2/neu; MLN 19; NEU proto-oncogene; P185erbB2; Tyrosine kinase receptor ErbB2; Tyrosine kinase-type cell surface receptor HER2; ERBB2
Target Type Successful
Gene Name ERBB2
Biochemical Class Kinase
UniProt ID ERBB2_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Breast cancer
Example drug Lapatinib Approved [538586], [541034], [1572592]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.49
Z-score: 1.12
P-value: 3.50E-77
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.35
Z-score: 0.62
P-value: 6.69E-13
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Example drug Afatinib Approved [529823], [541010], [1572592]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.13
Z-score: -0.19
P-value: 7.14E-04
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.11
Z-score: -0.14
P-value: 3.52E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Gastric cancer
Example drug Lapatinib Phase 3 [538585], [1572592]
Tissue Gastric tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.59
Z-score: 4.11
P-value: 2.78E-03
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.19
Z-score: 0.42
P-value: 1.77E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Bladder cancer
Example drug ABY-025 Phase 1/2 [524300], [1572592]
Tissue Bladder tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -1.26
Z-score: -2.05
P-value: 5.67E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Tissue Brainstem tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.21
Z-score: 1.79
P-value: 1.98E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Tissue White matter
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.15
Z-score: -0.94
P-value: 2.06E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 538585FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 538586FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
Ref 541010(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
Ref 541034(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
Ref 529823BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46.
Ref 524300ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health.
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.